Photocure $PHO.OL stock trade above resistance, close at 5yr hgh
Recent news by
PHO
:
Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
https://photocure.com/news/photocurefirst-trial-demonstrating-reduced-recurrence-after-flexible-blue-light-cystoscopy-with-hexvix-in-surveillance/
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
https://photocure.com/news/photocure-asa-results-for-the-third-quarter-of-2019/
Further improvements for US reimbursements for Cysview from january 2020:
https://photocure.com/news/photocure-cysview-reimbursement-further-improved-from-january-2020/
Technical analysis:
Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
PHO
: Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant:
https://photocure.com/news/photocurefirst-trial-demonstrating-reduced-recurrence-after-flexible-blue-light-cystoscopy-with-hexvix-in-surveillance/
At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris:
https://photocure.com/news/photocure-asa-results-for-the-third-quarter-of-2019/
Further improvements for US reimbursements for Cysview from january 2020:
https://photocure.com/news/photocure-cysview-reimbursement-further-improved-from-january-2020/
Technical analysis:
Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
